ArticleJournal of ophthalmic inflammation and infection2026
Evaluation and modulation of bactericidal potential of different antibacterial agents against bacterial pathogens from conjunctivitis infections.
Article in Journal of ophthalmic inflammation and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Barrier: Overcoming Ocular Antimicrobial Resistance Through AI and Novel Therapeutics.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conjunctivitis is one of the most common eye infections seen in hospitals. Youngsters under the age of seven, women at age 22 and men at age 28 are most likely to be diagnosed with this infection. The current study was designed to identify and characterize the conjunctivitis associated pathogens and to evaluate their sensitivity or resistance against commonly used antibiotics (metronidazole, ciprofloxacin, azithromycin, and levofloxacin), aqueous plant extracts (Ficus religiosa, Syzygium cumini, Azadirachta indica, Allium cepa, Eucalyptus camaldulensis, Syzygium aromaticum, Aloe barbadensis, and Citrus limon) and green synthesized silver nanoparticles. The samples were taken at Fatima Memorial Hospital, Lahore. Blood agar test was used for screening of alpha and beta hemolytic bacterial pathogens. Antibacterial activity against pathogenic isolates was done using well diffusion method. Antibiotics showed range of bactericidal potential against pathogens considerably more effective against isolated bacteria. Maximum antibacterial activity against bacterial strains was observed in E. camaldulensis, S. cumini, and C. limon (13.66 ± 1.20 to 9 ± 0.57, 15.5 ± 0.76 to 10.33 ± 1.45, and 21.33 ± 0.88 to 12.66 ± 0.33 respectively). Green synthesized silver nanoparticles showed better results as antibacterial agents with the zones of inhibition measuring 11.66 ± 0.66 to 8.83 ± 0.72; 12.5 ± 0.62 to 9.83 ± 0.72; 16.16 ± 1.09 to 10.83 ± 1.01; 13.33 ± 1.20 to 8.83 ± 0.72; 12.16 ± 1.16 to 7.33 ± 0.66, and 13.16 ± 0.59 to 8.33 ± 0.88 respectively. Biochemical and molecular characterization of pathogens was done. Bacterial strains were identified as Bacillus thuringiensis, Bacillus cereus, Bacillus paramycoides, Bacillus coahuilensis and Pseudomonas aeruginosa. This study showed that because of mis- use or over use of antibiotics, pathogens have developed resistance. So conventional medication may be replaced by biological antibacterial tools such as plant extracts and green synthesized silver nanoparticle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.